STOCK TITAN

ATAI Life Sciences N.V. Common Shares - ATAI STOCK NEWS

Welcome to our dedicated page for ATAI Life Sciences N.V. Common Shares news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on ATAI Life Sciences N.V. Common Shares stock.

ATAI Life Sciences N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of mental health disorders. Based in the United States and Germany, ATAI leverages a decentralized, technology- and data-driven platform to serve millions suffering from mental health challenges. The company’s mission is to develop innovative treatments that address significant unmet medical needs, leading to paradigm shifts in mental health care.

ATAI's product pipeline includes promising candidates such as COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. These candidates are designed to treat conditions such as depression, anxiety, addiction, and other mental health disorders.

Recently, ATAI announced positive results from its Phase 1 study of EMP-01, the R-enantiomer of MDMA. The study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EMP-01. Involving 32 healthy participants, the study showed that EMP-01 was well-tolerated with no severe adverse events. The PK profile was dose-proportional, and PD measures indicated significant, consistent, and dose-dependent changes. These promising results might pave the way for EMP-01’s further clinical development.

ATAI Life Sciences is committed to efficient drug development by pooling resources, expertise, and best practices across its portfolio. This approach helps mitigate risks and accelerates the development of impactful, evidence-based treatments. The company’s vision is to heal mental health disorders, enabling everyone to live a more fulfilled life.

For more information, visit their official website at www.atai.life.

Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) reported third quarter 2023 financial results and provided corporate updates. The company's $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. The Phase 2b study of RL-007 in CIAS patients is on track to report data in 2H 2024, and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. The company also announced the acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two novel 5-HT2A receptor agonists, EGX-A and EGX-B.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.13%
Tags
-
Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
management
-
Rhea-AI Summary
atai Life Sciences to participate in Jefferies Inaugural Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
conferences
Rhea-AI Summary
atai Life Sciences completes Phase 1 study of VLS-01, a DMT formulation, with favorable safety profile and comparable systemic delivery to IV administration. Plans to optimize formulation for Phase 2 study in treatment-resistant depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.1%
Tags
-
Rhea-AI Summary
atai Life Sciences to participate in the 2023 Cantor Fitzgerald Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
conferences
-
Rhea-AI Summary
atai Life Sciences to participate in upcoming September Investor Conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences
Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) reported Q2 2023 financial results and clinical program updates, highlighted by Phase 1 results of DMX-1002 for Opioid Use Disorder and a $227M cash position expected to fund operations into 1H 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
-
Rhea-AI Summary
atai Life Sciences announces results from Perception Neuroscience's Phase 1 study of PCN-101, a potential rapid-acting anti-depressant for at-home use
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
conferences
Rhea-AI Summary
atai Life Sciences reports Q1 2023 financial results and provides updates on clinical pipeline. RL-007 Phase 2b study initiated, GRX-917 shows potential anxiolytic effects, VLS-01 Phase 1 study expanded, COMP360 Phase 3 trial accelerated. $250M cash position expected to fund operations into 1H 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags

FAQ

What is the current stock price of ATAI Life Sciences N.V. Common Shares (ATAI)?

The current stock price of ATAI Life Sciences N.V. Common Shares (ATAI) is $1.52 as of November 21, 2024.

What is the market cap of ATAI Life Sciences N.V. Common Shares (ATAI)?

The market cap of ATAI Life Sciences N.V. Common Shares (ATAI) is approximately 256.9M.

What is ATAI Life Sciences N.V.?

ATAI Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders using innovative therapeutics.

Where is ATAI Life Sciences based?

ATAI Life Sciences operates in the United States and Germany.

What are some of ATAI Life Sciences' key products?

Key products include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, and EMP-01/MDMA derivative.

What recent achievement has ATAI announced?

ATAI recently announced positive results from its Phase 1 study of EMP-01, showing it to be well-tolerated with significant, consistent, and dose-dependent changes.

What is EMP-01?

EMP-01 is the R-enantiomer of MDMA, currently under clinical investigation for its potential to treat mental health disorders.

What is the mission of ATAI Life Sciences?

ATAI’s mission is to develop innovative treatments for mental health disorders, addressing significant unmet needs and leading to paradigm shifts in mental health care.

How does ATAI Life Sciences accelerate drug development?

ATAI pools resources, expertise, and best practices across its portfolio to mitigate risks and accelerate the development of impactful, evidence-based treatments.

What is the vision of ATAI Life Sciences?

ATAI’s vision is to heal mental health disorders so everyone can live a more fulfilled life.

How can I get more information about ATAI Life Sciences?

You can visit their official website at www.atai.life for more information.

ATAI Life Sciences N.V. Common Shares

Nasdaq:ATAI

ATAI Rankings

ATAI Stock Data

256.87M
151.01M
9.99%
26.83%
5.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BERLIN